The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas

Wang, Shuman; Wang, Aihua; Zhu, Kejing; Wang, Xiong; Chen, Yonggang; Wu, Jinhu

doi:10.1186/s12902-021-00900-9

Cited by 2 publications

(1 citation statement)

References 63 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In China, bromocriptine is a first-line drug against prolactinoma. Drug resistance frequently occurs, which brings clinical challenges (Wang et al, 2021; Xiao et al, 2020). Now that the pathogenesis of prolactinoma is unclear, drug development and therapeutic targets have occasion to be investigated imminently.…”

Section: Introductionmentioning

confidence: 99%

Network Pharmacology to Explore the Mechanism of Prunella vulgaris L. Against Prolactinoma

Meng,

Ni,

Cao

et al. 2023

Pharmacognosy Magazine

Self Cite

View full text Add to dashboard Cite

Objectives Prolactinoma is a common intracranial tumor with a high incidence and serious harm to human health. At present, there is only one therapeutic drug in China, bromocriptine, and the Chinese herb Prunella vulgaris L.( P. vulgaris)(PV) has shown certain anti-prolactinoma effects in the early stage. We expect to develop a candidate drug against prolactinoma. Materials and Methods First, the extracts of P. vulgaris L.(PVE)were extracted with water, and the cell proliferation test of rat pituitary tumor cells MMQ was checked by the Cell Counting Kit-8 (CCK-8) assay. Then, core targets and correlative pathways were selected by the “protein–protein interaction” (PPI) network and the “PV–Target–Prolactinoma” network. The core targets and main components simulate the binding by molecular docking. Finally, the PVE and MMQ cells were used to verify the results. Results Through the CCK-8 assay, the PVE inhibited the proliferation of MMQ cells. From the network pharmacology, the 21 targets, 9 signaling pathways, and 20 gene ontology (GO) projects were attained ( p < .05). As a result the estrogen receptor α (ESR1), RAC-alpha serine/threonine-protein kinase(AKT1), and mitogen-activated protein kinase 3(MAPK3)were the core targets of protein against prolactinomas, which was in line with western blotting analysis. Conclusion Our findings demonstrate that the PVE was verified against prolactinomas through the ESR1, MAPK3 targets, and the phosphoinositide 3-kinase/protein kinase B pathway.

show abstract

Section: Introductionmentioning

confidence: 99%

Network Pharmacology to Explore the Mechanism of Prunella vulgaris L. Against Prolactinoma

Meng,

Ni,

Cao

et al. 2023

Pharmacognosy Magazine

Self Cite

View full text Add to dashboard Cite

show abstract

Clinical features of hyperprolactinemia in children: modern methods of diagnosis and treatment

Абатуров¹,

Никулина²,

Alieinykova³

2022

View full text Add to dashboard Cite

Hyperprolactinemia is a common endocrine disease that can be associated with significant morbidity and disability in the population. A systematic review of literature sources on the diagnosis and treatment results in patients with hyperprolactinemia, including drug-resistant micro- and macroadenomas of the pituitary gland, was carried out in order to highlight the most significant practical recommendations. The purpose of this literature review is to provide algorithms for differential diagnosis and clinical observation of patients, to compare the efficacy and side effects of drugs, surgeries, and radiation therapy in the treatment of hyperprolactinemia. Prolactinomas are the most common pituitary adenomas in older children. Their share in the structure of pituitary adenomas is about 50 %. The clinical picture depends on the age, sex of the child, volume and characteristics of tumor growth. The leading clinical manifestations of hyperprolactinemia are disorders of the reproductive system, including signs of the development of secondary hypogonadotropic hypogonadism, sexual dysfunction, psychoemotional disorders, and endocrine and metabolic disorders. The main criterion for the diagnosis of hyperprolactinemia is the concentration of prolactin in the blood serum, which is above the upper limit of the physiological norm. The primary step in the treatment of patients with pituitary macroadenoma is to control the compression effects of the tumor, including compression of the optic chiasm, followed by restoration of gonadal function. The main areas of treatment for hyperprolactinemia are restoration and maintenance of the normal function of the gonads; restoration of fertility; prevention of osteoporosis. Dopamine receptor agonists are the gold standard in the treatment of hyperprolactinemia. However, some people do not respond satisfactorily to these drugs. In this case, in the presence of pituitary tumors, in addition to drug treatment, surgery and radiation therapy are used. But surgery and radiation therapy are not the primary methods of choice for the management of patients with prolactin-secreting pituitary adenomas; first of all, preference is given to drug therapy. The prognosis of the course of prolactinomas is favorable and is based on the results of dynamic observation and the presence of markers of the aggressiveness of this adenoma.

show abstract

The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas

Cited by 2 publications

References 63 publications

Network Pharmacology to Explore the Mechanism of Prunella vulgaris L. Against Prolactinoma

Network Pharmacology to Explore the Mechanism of Prunella vulgaris L. Against Prolactinoma

Clinical features of hyperprolactinemia in children: modern methods of diagnosis and treatment

Contact Info

Product

Resources

About